Intellia Therapeutics announced positive Phase 3 trial results for lonvoguran ziclumeran (lonvo-z), a CRISPR-based one-time treatment for hereditary angioedema (HAE). The trial showed an 87% reduction in monthly HAE attacks compared to placebo, with 62% of patients attack-free over six months. The treatment also improved patients' quality of life and demonstrated a favorable safety profile. Intellia is advancing lonvo-z toward FDA approval, expecting a U.S. launch in the first half of 2027.
Johnson & Johnson announced that the Phase 3 MonumenTAL-3 study demonstrated that TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, significantly improved progression-free survival (up to 81.3%) and overall survival (up to...
This week, retail investors showed strong interest in five stocks: SpaceX, Micron Technology, Advanced Micro Devices (AMD), Uber Technologies, and Super Micro Computer. SpaceX shares surged after its IPO, closing 19.3% higher on the first day. Micron...
FREELANDER 8 made its first public appearance at the Abu Dhabi Investment Forum in Shanghai, ahead of its official launch in Abu Dhabi. The vehicle, a premium intelligent all-terrain SUV co-created by Jaguar Land Rover and Chery, targets the Middle E...
SpaceX's historic market debut valued the company at about $2.1 trillion, sparking massive retail interest and record traffic on Robinhood. Jim Cramer predicts this could accelerate AI-related stock offerings, with companies like Anthropic potentiall...
Bitcoin's price has dropped to a 2026 low just under $60,000, down 53% from its October peak of $126,000, amid market volatility triggered by SpaceX's IPO and a prolonged sell-off in bitcoin ETFs. However, optimism is growing as BlackRock's $50 billi...
